How to buy Rexahn Pharmaceuticals stock

Rexahn Pharmaceuticals, Inc is a biotechnology business based in the US. Rexahn Pharmaceuticals shares (REXN) are listed on the NASDAQ and all prices are listed in US Dollars. Rexahn Pharmaceuticals employs 5 staff and has a trailing 12-month revenue of around USD$1.2 million.

How to buy shares in Rexahn Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Rexahn Pharmaceuticals. Find the stock by name or ticker symbol: REXN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rexahn Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rexahn Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Rexahn Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Rexahn Pharmaceuticals share price

Use our graph to track the performance of REXN stocks over time.

Rexahn Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-06.

52-week range	USD$1.72 - USD$14.8
50-day moving average	USD$7.198
200-day moving average	USD$9.5088
Wall St. target price	USD$3
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.834

Buy Rexahn Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Rexahn Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Rexahn Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rexahn Pharmaceuticals financials

Revenue TTM	USD$1.2 million
Gross profit TTM	USD$0
Return on assets TTM	-33.73%
Return on equity TTM	0%
Profit margin	0%
Book value	$2.925
Market capitalisation	USD$2 million

TTM: trailing 12 months

Shorting Rexahn Pharmaceuticals shares

There are currently 13,595 Rexahn Pharmaceuticals shares held short by investors – that's known as Rexahn Pharmaceuticals's "short interest". This figure is 358.8% up from 2,963 last month.

There are a few different ways that this level of interest in shorting Rexahn Pharmaceuticals shares can be evaluated.

Rexahn Pharmaceuticals's "short interest ratio" (SIR)

Rexahn Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rexahn Pharmaceuticals shares currently shorted divided by the average quantity of Rexahn Pharmaceuticals shares traded daily (recently around 271900). Rexahn Pharmaceuticals's SIR currently stands at 0.05. In other words for every 100,000 Rexahn Pharmaceuticals shares traded daily on the market, roughly 50 shares are currently held short.

However Rexahn Pharmaceuticals's short interest can also be evaluated against the total number of Rexahn Pharmaceuticals shares, or, against the total number of tradable Rexahn Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rexahn Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Rexahn Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0008% of the tradable shares (for every 100,000 tradable Rexahn Pharmaceuticals shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Rexahn Pharmaceuticals.

Find out more about how you can short Rexahn Pharmaceuticals stock.

Rexahn Pharmaceuticals share dividends

We're not expecting Rexahn Pharmaceuticals to pay a dividend over the next 12 months.

Have Rexahn Pharmaceuticals's shares ever split?

Rexahn Pharmaceuticals's shares were split on a 1:12 basis on 12 April 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rexahn Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Rexahn Pharmaceuticals shares which in turn could have impacted Rexahn Pharmaceuticals's share price.

Rexahn Pharmaceuticals share price volatility

Over the last 12 months, Rexahn Pharmaceuticals's shares have ranged in value from as little as $1.72 up to $14.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rexahn Pharmaceuticals's is 0.973. This would suggest that Rexahn Pharmaceuticals's shares are less volatile than average (for this exchange).

Rexahn Pharmaceuticals overview

As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.

Frequently asked questions

• What percentage of Rexahn Pharmaceuticals is owned by insiders or institutions?

  Currently 0.222% of Rexahn Pharmaceuticals shares are held by insiders and 8.326% by institutions.

• How many people work for Rexahn Pharmaceuticals?

  Latest data suggests 5 work at Rexahn Pharmaceuticals.

• When does the fiscal year end for Rexahn Pharmaceuticals?

  Rexahn Pharmaceuticals's fiscal year ends in December.

• Where is Rexahn Pharmaceuticals based?

  Rexahn Pharmaceuticals's address is: 15245 Shady Grove Road, Rockville, MD, United States, 20850

• What is Rexahn Pharmaceuticals's ISIN number?

  Rexahn Pharmaceuticals's international securities identification number is: US7616403090

• What is Rexahn Pharmaceuticals's CUSIP number?

  Rexahn Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 22003E100